{{drugbox
| Watchedfields = changed
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = U188XYD42P
| verifiedrevid = 462255811
| IUPAC_name = 1-cyclopropyl-7-[(1''S'',6''S'')-2,8-diazabicyclo[4.3.0]nonan-8-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid. 
| image = Moxifloxacin Structural Formulae V.1.svg
| image2 = Moxifloxacin-cation-from-xtal-3D-balls.png
| InChI = 1/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
| InChIKey = FABPRXSRWADJSP-MEDUHNTEBH
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 32
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FABPRXSRWADJSP-MEDUHNTESA-N
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 354812-41-2
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 134802
| NIAID_ChemDB = 070017
| ATC_prefix = J01
| ATC_suffix = MA14
| ATC_supplemental = {{ATC|S01|AE07}}
| PubChem = 152946
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00218
| chemical_formula =
| C=21 | H=24 | N=3 | F=1 | O=4
| molecular_weight = 401.431 [[Gram|g]]/[[Mole_(unit)|mol]]
| smiles = COc1c2c(cc(c1N3C[C@@H]4CCCN[C@@H]4C3)F)c(=O)c(cn2C5CC5)C(=O)O
| bioavailability = 86 to 92%
| protein_bound = 30 to 50%
| metabolism = [[Glucuronide|Glucuronide]] and [[sulfate|sulfate]] conjugation<br>[[Cytochrome_P450|Cytochrome P450]] system not involved
| elimination_half-life = 12 hours
| excretion = hepatic
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU =
| legal_UK =
| legal_US = Rx-only
| routes_of_administration = [[Route_of_administration#Enteral|Oral]], [[Intravenous_therapy|IV]], local (eyedrops)
| tradename = Avelox<br/>Vigamox, Moxeza (eye drops)
| Drugs.com = {{drugs.com|monograph|avelox}}
| MedlinePlus = a600002
| licence_US = Moxifloxacin
}}

'''莫西沙星'''（[[學名|學名]]：{{sname|moxifloxacin}}<ref name="drug-Avelox"/>）是一种由[[拜尔|拜尔]]公司开发的第四代人工合成的[[喹诺酮|喹诺酮]]类[[抗细菌药|抗细菌药]]（8-methoxy-fluoroquinolone類抗生素<ref name="tma-2001-44-12"/><ref name="ysp-201502-09"/>）。其口服剂（以'''盐酸莫西沙星'''之形式）在世界范围内以 Avelox、Avalox 和 Avelon 等商标名贩售，在大多数国家也有静脉注射剂。该药也有治疗[[结膜炎|结膜炎]]（红眼病）的眼药水，商标名为 Vigamox 和 Moxeza<ref name="tcdruginfo-Moxifloxacin"/>。其殺菌作用藉由干擾[[拓撲異構酶|拓撲異構酶]]（topoisomerase），進而抑制[[DNA|DNA]]合成，最終導致[[細菌|細菌]]死亡，1999年12月由[[FDA|FDA]]核准上市<ref name="ysp-201502-09"/>。

莫西沙星可用于治疗几种感染症，包括[[呼吸道感染|呼吸道感染]]、[[蜂窝组织炎|蜂窝组织炎]]、[[炭疽病|炭疽病]]、[[心内膜炎|心内膜炎]]、腹腔内感染、[[脑膜炎|脑膜炎]]及[[结核病|结核病]]<ref name=AHFS>{{cite web|title=Avelox|url=http://www.drugs.com/monograph/avelox.html|work=The American Society of Health-System Pharmacists|accessdate=2015-10-02|archive-date=2018-12-11|archive-url=https://web.archive.org/web/20181211103637/https://www.drugs.com/monograph/avelox.html|dead-url=no}}</ref>。

其主要機轉作用於[[DNA旋转酶|DNA旋转酶]]的gyrA subunit，不同於[[左氧氟沙星|左氧氟沙星]]（levofloxacin）、[[氧氟沙星|氧氟沙星]]（ofloxacin）等的 fluoroquinolones 類抗生素，其作用則在拓撲異構酶IV（topoisomerase IV）的 parC 或是 parE subunit<ref name="ysp-201502-09"/><ref>{{cite web|url=http://www.ncbi.nlm.nih.gov/pubmed/8891124 |title=ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit i... |accessdate= 2015-11-03 | publisher=PubMed - [[美国国家生物技术信息中心|NCBI]]  |language=en}}</ref><ref>{{cite web|url= http://prodata.swmed.edu/Lab/Research.htm |title= Grishin Lab: Research |date=2015-04-30|accessdate= 2015-11-03 | publisher={{tsl|en|University of Texas Southwestern Medical Center|德克薩斯大學西南醫學中心|University of Texas Southwestern Medical Center}} |language=en}}</ref>。

==潛在副作用==
*[[腱|肌腱]]斷裂的風險，可能有肌腱疼痛，發炎等症狀。<ref name="ysp-201502-09"/><ref name="tcdruginfo-Moxifloxacin"/>
*[[重症肌無力|重症肌無力]]惡化。<ref name="ysp-201502-09"/><ref name="tcdruginfo-Moxifloxacin"/>
*[[光毒性|光毒性]]<ref name="ysp-201502-09"/><ref name="tcdruginfo-Moxifloxacin"/>
*[[長QT綜合症|長QT綜合症]]
*主动脉破裂或撕裂<ref>https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics</ref>

==参考资料==
{{reflist|1|refs=
<ref name="drug-Avelox">{{cite web|title=Avelox: Uses, Dosage & Side Effects |url=http://www.drugs.com/avelox.html |work=The American Society of Health-System Pharmacists|accessdate=2015-11-01 |publisher=Drugs.com }}</ref>
<ref name="tma-2001-44-12">{{cite web |url= http://www.tma.tw/ltk/90440712.htm |title= Fluoroquinolone類抗生素新觀與分類 |author= 施議強 |coauthors= 許清曉、侯承伯 |work= 《台灣醫界》, Vol.44, No.12 |publisher= 中華民國醫師公會全國聯合會 |date= 2001 |origyear= 2001 |accessdate= 2015-11-01 |language= zh |archive-url= https://web.archive.org/web/20160304192704/http://www.tma.tw/ltk/90440712.htm |archive-date= 2016-03-04 |dead-url= yes }}{{zh-tw }}</ref>
<ref name="ysp-201502-09">{{cite web| url= http://www.ysp.com.tw/ysp/Product-Medicine-01.aspx?tc=6b&volumn=201502&sn=9 |title= Moxifloxacin簡介與治療概況 |author=  |coauthors=  | work=《永信藥訊》2015年2月號 | publisher= [[永信藥品|永信藥品]] |date=2015-02-01|origyear= 2015|accessdate=2015-11-02 |language=zh}}{{zh-tw }}</ref>
<ref name="tcdruginfo-Moxifloxacin">{{cite web| url=http://www.tcdruginfo.com/My%20Webs%5CMoxifloxacin.html |title= MOXIFLOXACIN |author=  |coauthors= | publisher=全球華人藥物資訊網 |accessdate=2015-11-02 |language=zh}}{{zh-tw }}、[http://www.tcdruginfo.com/Simple/&Moxifloxacin.html {{zh-cn}}]</ref>
}}

{{核酸合成抑制剂类抗生素}}
[[Category:喹诺酮抗生素|Category:喹诺酮抗生素]]

[[Category:拜耳|Category:拜耳]]